Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Biomark Diagnostics Inc. (C:BUX)

Business Focus: Bio Diagnostics & Testing

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for BUX within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 15, 2024 08:30 ET
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research at 2024 GPEN Conference
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early detection of hard-to-detect and treat cancers, is pleased to announce today that long time collaborators at the University of Manitoba Therapeutics will be presenting this week compelling new research findings on glioblastoma at the 2024 Globalization of Pharmaceutics Education Network (GPEN) Conference in Copenhagen from July 14-17, 2024.
Read full article
Apr 18, 2024 08:30 ET
BioMark Announces Warrant Extension and Granting of Options
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce that the Company intends to amend the terms of 5,062,000 the non-broker warrants (the "Warrants") issued to a private placement financing that closed on May 4th, 2022. The Warrants currently carry an exercise price per share of C$0.45 and are scheduled to expire on May 4th, 2024.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
-0.25
--
--
Price to Sales - TTM
122.54
--
3.75
Price to Book - most recent quarter
--
--
2.20
Price to Cash Flow per share - TTM
--
--
11.23
Price to Free Cash Flow per share - TTM
--
--
18.95
See all valuations

Short Report

Date Number of Shares Shorted Net Change
Jun 30, 2024 279 -1,000
Jun 15, 2024 1,279 812
May 31, 2024 467 -2,803
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. It has also developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.

See business summary

 

Twitter

Search (past week) for $BUX.CA

  • No tweets found